Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (291-300 of 459) with videos related to

Pageof 46
Sort By:
Cancer Treatment Reviews|March 15, 2016
Metabolic phenotype of bladder cancerFrancesco Massari, Chiara Ciccarese, Matteo Santoni, et al.
ISRN Oncology|March 21, 2014
[ (11) C]-methionine positron emission tomography in the postoperative imaging and followup of patients with primary and recurrent gliomasMatteo Santoni, Cristina Nanni, Alessandro Bittoni, et al.
Current Drug Metabolism|October 16, 2015
Metabolic Alterations in Renal and Prostate CancerChiara Ciccarese, Matteo Santoni, Francesco Massari, et al.
Targeted Oncology|October 3, 2015
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-AnalysisRoberto Iacovelli, Franco Nolè, Elena Verri, et al.
The Prostate|May 19, 2015
Metabolic syndrome in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Lisa Derosa, et al.
Future Oncology (London, England)|November 7, 2015
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysisAnnalisa Guida, Cristina Masini, Michele Milella, et al.
Drugs in R&D|May 24, 2026
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine TumorsJavier Molina-Cerrillo, Arantzazu Sierra-Ramirez, José L López-Aceituno, et al.
Oncoscience|June 23, 2015
Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cellsConsuelo Amantini, Maria Beatrice Morelli, Matteo Santoni, et al.
Cancer Treatment Reviews|July 15, 2015
Metabolic alterations in renal cell carcinomaFrancesco Massari, Chiara Ciccarese, Matteo Santoni, et al.
Cancers|April 3, 2019
The Human Microbiota and Prostate Cancer: Friend or Foe?Francesco Massari, Veronica Mollica, Vincenzo Di Nunno, et al.
Pageof 46

Showing results (291-300 of 459) with videos related to

Sort By:
Pageof 46
Cancer Treatment Reviews|March 15, 2016
Metabolic phenotype of bladder cancerFrancesco Massari, Chiara Ciccarese, Matteo Santoni, et al.
ISRN Oncology|March 21, 2014
[ (11) C]-methionine positron emission tomography in the postoperative imaging and followup of patients with primary and recurrent gliomasMatteo Santoni, Cristina Nanni, Alessandro Bittoni, et al.
Current Drug Metabolism|October 16, 2015
Metabolic Alterations in Renal and Prostate CancerChiara Ciccarese, Matteo Santoni, Francesco Massari, et al.
Targeted Oncology|October 3, 2015
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-AnalysisRoberto Iacovelli, Franco Nolè, Elena Verri, et al.
The Prostate|May 19, 2015
Metabolic syndrome in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Lisa Derosa, et al.
Future Oncology (London, England)|November 7, 2015
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysisAnnalisa Guida, Cristina Masini, Michele Milella, et al.
Drugs in R&D|May 24, 2026
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine TumorsJavier Molina-Cerrillo, Arantzazu Sierra-Ramirez, José L López-Aceituno, et al.
Oncoscience|June 23, 2015
Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cellsConsuelo Amantini, Maria Beatrice Morelli, Matteo Santoni, et al.
Cancer Treatment Reviews|July 15, 2015
Metabolic alterations in renal cell carcinomaFrancesco Massari, Chiara Ciccarese, Matteo Santoni, et al.
Cancers|April 3, 2019
The Human Microbiota and Prostate Cancer: Friend or Foe?Francesco Massari, Veronica Mollica, Vincenzo Di Nunno, et al.
Pageof 46